Given the sensitivity of SMARCB1-deficient tumors to EZH2 inhibition, and the diminution of SMARCB1 levels observed in SS18-SSX translocation positive synovial sarcomas, we hypothesized that synovial sarcomas may be similarly dependent on PRC2/EZH2 activity. The gene discussed is SSX2; the disease is synovial sarcoma.